J&J Medtech Appoints Kurt Van den Bosch As CFO
Kurt Van den Bosch has been named CFO of J&J Medtech where he will report directly to Joe Wolk, J&J’s CFO.
You may also be interested in...
J&J To Split Consumer From Medtech and Pharmaceutical Businesses – Creating Two Companies To Unlock More Value, Growth, Innovation
Johnson & Johnson expects that the new J&J unit will be better positioned to share expertise such as combing medical devices with drugs and continue to innovate.
Smith + Nephew is expanding its suite of simulation technologies to train surgeons on new techniques before they enter the operating room.
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.